Bulbar onset ALS is a type of amyotrophic lateral sclerosis (ALS) that occurs due to the loss of motor neurons in the bulbar region of the brainstem. This progressive condition affects speech, ...

When the results of the first-ever platform trial for amyotrophic lateral sclerosis (ALS) were published this February, the headlines might have seemed disappointing: four experimental drugs failed to ...

New hope could be on the horizon for ALS patients in the form of a "breakthrough" drug, researchers say. Neuvivo, a California biopharmaceutical company that develops therapies for neurodegenerative ...

In March 2009, after a long night on duty at the hospital, Emmeline Lagrange took a deep breath and prepared to place a devastating phone call. Lagrange, a neurologist, had diagnosed a 42-year-old ...

A stem-cell-based "organ-on-a-chip" model of ALS mimics early biological changes seen in the degenerative disease. When you purchase through links on our site, we may earn an affiliate commission.

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Researchers have found that patients with amyotrophic lateral sclerosis have ...

A simple non-invasive hair-based test could one day help with early diagnosis of amyotrophic lateral sclerosis (ALS)—improving patient care and potentially extending survival. This is the hope of ...

Historically, people with amyotrophic lateral sclerosis (ALS) experience a relentless decline in neurological function that eventually robs them of the ability to move, speak, eat or breathe. Now, ...

In 2017, at age 37, Brian Wallach, a former attorney in the Obama administration, was diagnosed with amyotrophic lateral sclerosis (ALS), a progressive, incurable neurodegenerative disease — and was ...

In April, the co-CEOs of Amylyx Pharmaceuticals fulfilled a promise they made years earlier to people with the deadly disease ALS. Justin Klee and Josh Cohen, who started Amylyx while they were ...